NASDAQ:VKTX - Viking Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$10.45 -0.09 (-0.85 %)
(As of 08/20/2018 02:29 AM ET)
Previous Close$10.45
Today's Range$10.38 - $10.71
52-Week Range$0.97 - $13.43
Volume972,328 shs
Average Volume2.27 million shs
Market Capitalization$628.41 million
P/E Ratio-13.23
Dividend YieldN/A
Beta2.74
Viking Therapeutics logoViking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead clinical program, VK5211, is an orally available, non-steroidal selective androgen receptor modulator in Phase II development for the treatment of patients recovering from non-elective hip fracture surgery; in Phase I clinical trials for improving lean body mass; and in pre-clinical trial for improving bone mineral density, bone mineral content, bone strength, and other measures. The company is also developing VK2809, an orally available, tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in a Phase II clinical trial for the treatment of patients with hypercholesterolemia and fatty liver disease; and in a Phase I clinical trial to treat patients who suffer from glycogen storage disease type Ia. In addition, it is developing VK0214 for X-linked adrenoleukodystrophy, which is in pre-clinical stage. Viking Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California.

Receive VKTX News and Ratings via Email

Sign-up to receive the latest news and ratings for VKTX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:VKTX
CUSIPN/A
Phone858-704-4660

Debt

Debt-to-Equity RatioN/A
Current Ratio35.18
Quick Ratio35.18

Price-To-Earnings

Trailing P/E Ratio-13.23
Forward P/E Ratio-24.88
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.38 per share
Price / Book27.50

Profitability

EPS (Most Recent Fiscal Year)($0.79)
Net Income$-20,570,000.00
Net MarginsN/A
Return on Equity-35.70%
Return on Assets-31.72%

Miscellaneous

Employees14
Outstanding Shares60,660,000
Market Cap$628.41 million

Viking Therapeutics (NASDAQ:VKTX) Frequently Asked Questions

What is Viking Therapeutics' stock symbol?

Viking Therapeutics trades on the NASDAQ under the ticker symbol "VKTX."

How were Viking Therapeutics' earnings last quarter?

Viking Therapeutics Inc (NASDAQ:VKTX) posted its quarterly earnings data on Thursday, August, 9th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.11) by $0.02. View Viking Therapeutics' Earnings History.

When is Viking Therapeutics' next earnings date?

Viking Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, November, 14th 2018. View Earnings Estimates for Viking Therapeutics.

What price target have analysts set for VKTX?

7 brokerages have issued 1 year target prices for Viking Therapeutics' stock. Their forecasts range from $13.00 to $15.00. On average, they expect Viking Therapeutics' share price to reach $14.3333 in the next twelve months. This suggests a possible upside of 37.2% from the stock's current price. View Analyst Price Targets for Viking Therapeutics.

What is the consensus analysts' recommendation for Viking Therapeutics?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Viking Therapeutics in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Viking Therapeutics.

What are Wall Street analysts saying about Viking Therapeutics stock?

Here are some recent quotes from research analysts about Viking Therapeutics stock:
  • 1. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and $15 price target. Our price target is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Factors which could impede reaching our price target include failed or inconclusive clinical trials or inability of the company to secure adequate funding to progress its drugs through the development pathway. Viking Therapeutics, Inc." (8/10/2018)
  • 2. Maxim Group analysts commented, "Viking reported 4Q17 with a net loss of $4.1M and ended the period with $20.6M in cash excluding the $63M capital raise in February. Based on our estimate of $23M-$25M per year in operating expenses, Viking has runway into mid-2020. We believe the strong cash position strengthens possible deal terms with a partner for the pivotal trial." (3/8/2018)

Who are some of Viking Therapeutics' key competitors?

Who are Viking Therapeutics' key executives?

Viking Therapeutics' management team includes the folowing people:
  • Dr. Brian Lian, Pres, CEO & Director (Age 52)
  • Mr. Michael Morneau, VP of Fin. & Admin. (Age 53)
  • Ms. Amy Broidrick, Sr. VP of Corp. Devel.
  • Dr. Hiroko Masamune, Chief Devel. Officer (Age 61)
  • Ms. Marianne Mancini, Sr. VP of Clinical Operations

When did Viking Therapeutics IPO?

(VKTX) raised $20 million in an initial public offering on Wednesday, April 29th 2015. The company issued 2,500,000 shares at $7.00-$9.00 per share. Laidlaw & Company (UK) Ltd. served as the underwriter for the IPO and Feltl and Company was co-manager.

Has Viking Therapeutics been receiving favorable news coverage?

Press coverage about VKTX stock has been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern identifies positive and negative media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Viking Therapeutics earned a news impact score of 0.20 on Accern's scale. They also gave news stories about the biotechnology company an impact score of 48.11 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future. View Recent Headlines for Viking Therapeutics.

Who are Viking Therapeutics' major shareholders?

Viking Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Boxer Capital LLC (6.18%), BlackRock Inc. (4.85%), Janus Henderson Group PLC (3.40%), Opaleye Management Inc. (1.98%), Acuta Capital Partners LLC (1.24%) and Millennium Management LLC (1.22%). Company insiders that own Viking Therapeutics stock include J Matthew Singleton, Lawson Macartney, Matthew W Foehr and Michael Morneau. View Institutional Ownership Trends for Viking Therapeutics.

Which major investors are selling Viking Therapeutics stock?

VKTX stock was sold by a variety of institutional investors in the last quarter, including Sio Capital Management LLC, Millennium Management LLC, EAM Global Investors LLC and Bank of America Corp DE. View Insider Buying and Selling for Viking Therapeutics.

Which major investors are buying Viking Therapeutics stock?

VKTX stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Janus Henderson Group PLC, Acuta Capital Partners LLC, Pier Capital LLC, Boxer Capital LLC, Macquarie Group Ltd., Bank of New York Mellon Corp and Asymmetry Capital Management L.P.. Company insiders that have bought Viking Therapeutics stock in the last two years include J Matthew Singleton, Lawson Macartney and Matthew W Foehr. View Insider Buying and Selling for Viking Therapeutics.

How do I buy shares of Viking Therapeutics?

Shares of VKTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Viking Therapeutics' stock price today?

One share of VKTX stock can currently be purchased for approximately $10.45.

How big of a company is Viking Therapeutics?

Viking Therapeutics has a market capitalization of $628.41 million. The biotechnology company earns $-20,570,000.00 in net income (profit) each year or ($0.79) on an earnings per share basis. Viking Therapeutics employs 14 workers across the globe.

How can I contact Viking Therapeutics?

Viking Therapeutics' mailing address is 12340 EL CAMINO REAL SUITE 250, SAN DIEGO CA, 92130. The biotechnology company can be reached via phone at 858-704-4660 or via email at [email protected]


MarketBeat Community Rating for Viking Therapeutics (NASDAQ VKTX)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  215 (Vote Outperform)
Underperform Votes:  125 (Vote Underperform)
Total Votes:  340
MarketBeat's community ratings are surveys of what our community members think about Viking Therapeutics and other stocks. Vote "Outperform" if you believe VKTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VKTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/20/2018 by MarketBeat.com Staff

Featured Article: Leveraged Buyout (LBO)

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel